Evogene Ltd. (EVGN) Form 6-K — Oct 28, 2026
Evogene announced acute graft-versus-host disease (aGVHD) as the target indication for its internal AI-driven drug discovery program, aiming to develop a potential first-in-class small-molecule therapy for steroid-refractory patients using its ChemPass AI™ platform. Within months, the company generated novel, patentable small-molecule candidates showing nanomolar potency and favorable ADME/toxicology profiles, after exploring a virtual chemical space of more than 110 billion molecules. The program is guided by leading experts Dr. Corey Cutler of Dana-Farber and Prof.
Key figures
- Virtual chemical space explored
- over 110 billion molecules
- Steroid refractory a GVHD mortality
- up to 50%
- A GVHD incidence transplant recipients
- 30%-40%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.